Market closed

REGENXBIO/$RGNX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About REGENXBIO

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Ticker

$RGNX
Trading on

Industry

Biotechnology

Employees

344

REGENXBIO Metrics

BasicAdvanced
$573M
Market cap
-
P/E ratio
-$5.00
EPS
1.23
Beta
-
Dividend rate
$573M
1.23
$28.80
$8.54
560K
3.051
2.717
36.957
48.375
-52.13%
-26.03%
-71.87%
6.551
1.9
1.9
-2.99
-15.14%
-16.56%
-3.26%
-1.12%

What the Analysts think about REGENXBIO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.

REGENXBIO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

REGENXBIO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGNX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for REGENXBIO stock?

REGENXBIO (RGNX) has a market cap of $573M as of November 13, 2024.

What is the P/E ratio for REGENXBIO stock?

The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of November 13, 2024.

Does REGENXBIO stock pay dividends?

No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next REGENXBIO dividend payment date?

REGENXBIO (RGNX) stock does not pay dividends to its shareholders.

What is the beta indicator for REGENXBIO?

REGENXBIO (RGNX) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.